Lupin gets USFDA nod to market drug used to treat chronic hepatitis B
The company has received tentative approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application for Tenofovir Alafenamide tablets (25 mg), Lupin said in a statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Hepatitis | Hepatitis B | New Drug Applications | Pharmaceuticals | USA Health | Viread